Keytruda rules the immunotherapy market, but challengers are lining up – STAT

Posted by on September 22, 2020 9:08 am
Tags:
Categories: Crispr Articles

Source: Keytruda rules the immunotherapy market, but challengers are lining up – STAT

Keytruda is the immunotherapy king. In the U.S., the Merck anti-PD1 checkpoint inhibitor is approved to treat 16 cancers and has 26 indications overall. Sales were $11 billion in 2019 and $6.7 billion through the first half of this year. Keytruda is not only the most successful cancer drug ever developed, but it ranks among the best medicines ever.

That hasn’t stopped competitors from taking shots at it. A big part of this year’s annual meeting of the European Society for Medical Oncology, which concluded yesterday, involved data presentations from rival drug makers trying to show their medicines can stand up to Keytruda. None of these are direct, head-to-head clinical trials — don’t hold your breath for those being done — but all of the studies still involve Keytruda because it’s the real-world measuring stick.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

| Learn More

What is it?

STAT Plus is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Published at Tue, 22 Sep 2020 08:58:36 +0000

< Immunotherapy Today home